Alnylam’s heart drug troubles take center stage at a cardiology conference

The reporting (11)

• 
  Why is Alnylam Pharmaceuticals stock sliding today? Investing.com · 26d ago
• 
  Alnylam stock drops on rival heart trial: Why analysts see core business safe Investing.com · 26d ago
• 
  AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease BioPharma Dive · 26d ago
• 
  ‘Worse than expected’ Wainua data muddies water for TTR silencers BioSpace · 26d ago
• 
  AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching STAT · 26d ago broke it first
• 
  CARDIO-TTRansform trial investigating eplontersen fails to meet primary efficacy endpoint News-Medical · 26d ago
• 
  Is Alnylam (ALNY) Turning Expanded HELIOS-B and Zilebesiran Data Into Durable Cardiovascular Leadership? Yahoo Finance · 26d ago
• 
  Alnylam drops as Astra posts trial data for failed heart drug Seeking Alpha · 26d ago
• 
  Future of AstraZeneca’s gene silencer in heart disease uncertain after trial failure Endpoints News · 26d ago
• 
  In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs STAT · 26d ago broke it first
• 
  Alnylam’s heart drug troubles take center stage at a cardiology conference STAT · 26d ago broke it first

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Related trends